Johnson & Johnson Completes $3.05B Halda Therapeutics Deal

Johnson & Johnson has completed a major strategic acquisition that strengthens its long-term oncology ambitions and reinforces its leadership in innovative medicine. The healthcare major announced the successful completion of its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for $3.05 billion.

The transaction adds Halda’s proprietary Regulated Induced Proximity Targeting Chimera (RIPTAC) platform to Johnson & Johnson’s research capabilities, enabling the development of oral, targeted therapies for multiple solid tumours, including prostate cancer.

“This strategic milestone underscores our commitment to redefining cancer treatment with breakthrough science and transformative medicines,” said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson. “We are excited to formally welcome the talented Halda team to Johnson & Johnson and look forward to working together to achieve our shared goal of eliminating cancer.”

Also Read: Advancing Interventional Radiology in India Through Collaboration

With the acquisition, Johnson & Johnson gains HLD-0915, a clinical-stage, once-daily oral therapy for prostate cancer, building on nearly two decades of focused innovation in the disease area. The company also adds several earlier-stage candidates targeting breast, lung and other tumour types, expanding the depth of its oncology pipeline. The RIPTAC technology may also enable the development of targeted therapies beyond oncology.

“Johnson & Johnson continuously seeks new ways to meet patient needs and deliver innovative therapies,” said John C. Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, R&D, Johnson & Johnson. “Now that we have finalized this acquisition, we will focus.”

The acquisition will be accounted for as a business combination, with Johnson & Johnson expecting earnings dilution across 2025 and 2026. The company plans to provide detailed guidance during its fourth-quarter earnings call on January 21, 2026.